Dr. Shurjeel Choudhri

Senior Vice President and Head, Medical and Scientific Affairs

Bayer Inc

Senior Vice President and Head, Medical and Scientific Affairs at Bayer Inc., Innovative Medicines Canada Representative.

Dr. Choudhri is Senior Vice President and Head, Medical and Scientific Affairs at Bayer Inc. He joined Bayer Corporation in 1999 and has had significant experience with the Bayer US medical and Global Development organizations. Before assuming his current role as Head of Medical and Scientific Affairs (M&SA) in Canada, Dr. Choudhri was the Global Clinical Leader, Anti-Infectives with the Bayer Global Clinical Development group. As Head of M&SA for Bayer Inc Dr. Choudhri is responsible for contributing to the Canadian and International development, registration, and post-registration scientific/medical support for Bayer’s pharmaceutical products.

Dr. Choudhri obtained his MD from the University of Manitoba and also did his specialty training in Internal Medicine and sub-specialty training in Infectious Diseases in Manitoba. He then completed a senior research fellowship in Nairobi, Kenya and in1996 was awarded the Young Investigator Award by the Canadian Association of HIV Researchers. Dr. Choudhri has authored or co-authored over 100 scientific abstracts and has contributed to over 40 publications in peer reviewed journals.

Prior to joining Bayer, he was an Assistant professor in the Departments of Medical Microbiology and Internal Medicine at the University of Manitoba, Director of the HIV/AIDS program at the St. Boniface General Hospital and the Manitoba Satellite Director for the Canadian HIV Clinical Trials Network.


All Sessions by Dr. Shurjeel Choudhri

Printer Friendly See Full Agenda

Day 1: Oct 6, 2020

Day 2: Oct 7, 2020

1:40 pm

1:40 pm

Panel Discussion

The Patient perspective – Instil the Patients’ Voice into Your Market Access Strategy to Enhance Your Product’s Success

Involving patient groups has become a cornerstone to the success of new product launches.  Advance the validity of your R&D results, RWE and your market access strategy by incorporating the patient voice from the earliest possible stage of development.  Create a blueprint to:

  • Initiate greater collaboration with patient groups earlier on to engage them within the boundaries of compliance
  • Understand the benefits of involving patients in the trial design stage
  • Gain early insight into how patients react to your product that can enhance your success throughout your development cycle, submission processes and beyond to patient support

Instil the patients’ voice into your R&D to advance your market access strategy

Day 3: Oct 8, 2020